Modeling Management Strategies for Clinical Stage I Seminoma: Direct and Indirect Costs for the First 5 Years

• Published in: Urology practice 2014-09, Vol.1 (3), p.151-155
• Main Authors: Pham, Khanh N, Johnston, Richard B, Jeldres, Claudio, Nichols, Craig R, Porter, Christopher R
• Format: Article
• Language: English
• ISSN: 2352-0787
• DOI: 10.1016/j.urpr.2014.05.006

Clinical stage I seminoma can be managed with surveillance, chemotherapy or radiotherapy with similar survival rates. However, costs and side effects vary among these treatment modalities. We created a model to estimate the direct and indirect costs during the first 5 years of treatment for the 3 treatment strategies. Markov model based analyses were conducted to compare the costs of the 3 management strategies during the first 5 years. In this model clinicians and patients were assumed to be 100% compliant with the 2012 NCCN Guidelines for testicular cancer. Model parameters were collected from the Washington State CHARS (Comprehensive Hospital Abstract Reporting System), published literature and Medicare reimbursement amounts. A 5% annual health inflation rate was assumed. The model predicts an initial cost premium for carboplatin (1 cycle-$9,199.49; 2 cycles-$10,613.85) and radiotherapy ($9,532.80) compared with surveillance ($9,065.31). Radiotherapy (145.8 hours) and surveillance (123.0 hours) require more patient time than carboplatin (1 cycle-93.2 hours, 2 cycles-106.3 hours). When the direct and indirect costs are considered, the least expensive management strategy is surveillance. Surveillance is the most cost-effective management strategy for clinical stage I seminoma during the first 5 years of treatment. Although not evaluated in this analysis, costs of late side effects associated with radiotherapy and chemotherapy should be considered. Due to potentially minimal late side effects and superior cost-effectiveness, surveillance represents a safe, cost-effective and time effective option for the management of stage I seminoma.